Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

NCT03622775 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped \<75% participation

Conditions

Recurrent Plasma Cell Myeloma

Interventions

BIOLOGICAL: Daratumumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]